Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
This study has been completed.
Sponsor:
Pharmacyclics
Information provided by (Responsible Party):
Pharmacyclics
ClinicalTrials.gov Identifier:
NCT00121420
First received: July 14, 2005
Last updated: September 11, 2012
Last verified: May 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.
Condition | Intervention | Phase |
---|---|---|
Neoplasm Metastasis Brain Neoplasms |
Drug: Motexafin gadolinium |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases |
Resource links provided by NLM:
Further study details as provided by Pharmacyclics:
Primary Outcome Measures:
- Rate of irreversible Grade 3 or any Grade 4 or 5 neurologic radiation toxicities occurring within 3 months following SRS boost.
Secondary Outcome Measures:
- Change in lesion size and number between screening MRI and SRS treatment-planning MRI
- Time to neurologic progression or death with evidence of neurologic progression
- Time to neurocognitive progression
- Time to all-cause mortality
Estimated Enrollment: | 45 |
Patients will receive three weeks of whole brain radiation therapy concurrent with daily motexafin gadolinium during weeks 2 and 3, followed by a stereotactic radiosurgery boost concurrent with motexafin gadolinium. Patients will be followed for radiologic response, neurologic progression, and neurocognitive progression.
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Karnofsky performance status (KPS) ≥ 70
- Histologically confirmed malignancy with the presence of one to four intraparenchymal brain metastases
- Each patient must sign a study-specific Informed Consent form
Exclusion Criteria:
- Previous cranial radiation
- Complete resection of all known brain metastases
- Known leptomeningeal metastases
- Known liver metastases
- Clinical or radiologic evidence of progression (other than study lesion[s) within 1 month prior to enrollment
- Patients with metastases within 10 mm of the optic apparatus
- Patients with metastases in the brainstem, midbrain, pons, or medulla
- Planned chemotherapy during WBRT and/or SRS
- Uncontrolled hypertension
- Women who are pregnant or lactating
and Laboratory values as follows:
- LDH > 1.3 x upper limit of normal (ULN)
- ANC < 1500/mm3
- Platelets < 50,000/mm3
- Creatinine > 2.0 mg/dL
- AST or ALT > 3 x ULN
- Total bilirubin > 2 x ULN
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00121420
Locations
United States, Arizona | |
Phoenix, Arizona, United States | |
United States, Colorado | |
Aurora, Colorado, United States | |
United States, Ohio | |
Cleveland, Ohio, United States | |
Columbus, Ohio, United States | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States | |
United States, Texas | |
Dallas, Texas, United States | |
Houston, Texas, United States | |
United States, Wisconsin | |
Madison, Wisconsin, United States | |
Milwaukee, Wisconsin, United States | |
Canada, Quebec | |
Montreal, Quebec, Canada | |
Quebec City, Quebec, Canada | |
Sherbrooke, Quebec, Canada |
Sponsors and Collaborators
Pharmacyclics
Investigators
Study Chair: | Minesh P Mehta, MD | University of Wisconsin, Madison |
More Information
Additional Information:
Publications:
Keywords provided by Pharmacyclics:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
Additional Information:
Pharmacyclics 
Publications:
Responsible Party: | Pharmacyclics |
ClinicalTrials.gov Identifier: | NCT00121420 History of Changes |
Other Study ID Numbers: | PCYC-0224 |
Study First Received: | July 14, 2005 |
Last Updated: | September 11, 2012 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by Pharmacyclics:
Brain Neoplasms/secondary Brain neoplasms/radiotherapy Brain metastasis Neoplasm metastasis Cranial irradiation Radiosurgery |
Lung Neoplasms Breast Neoplasms Kidney Neoplasms Melanoma Radiotherapy Carcinoma, non-small cell lung |
Additional relevant MeSH terms:
Brain Neoplasms Neoplasms Neoplasm Metastasis Neoplasms, Second Primary Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Neoplastic Processes Pathologic Processes Motexafin gadolinium Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Photosensitizing Agents Radiation-Sensitizing Agents Physiological Effects of Drugs Dermatologic Agents |
ClinicalTrials.gov processed this record on October 16, 2012